PipelineReview.com15h
Oral semaglutide demonstrates a 14% reduction in risk of major adverse cardiovascular events in adults with type 2 diabetes in the SOUL trial
BAGSVAERD, Denmark I1, 2024 I Novo Nordisk today announced the headline results from the SOUL cardiovascular outcomes trial. The double-blinded, ...
Study finds comorbid diabetes increases risk for lower extremity amputation with kidney disease
Patients with comorbid diabetes have an elevated risk for lower extremity amputation (LEA) at all stages of chronic kidney ...
EuropaWire19h
Novo Nordisk’s Oral Semaglutide Reduces Cardiovascular Risk by 14% in Type 2 Diabetes Patients, SOUL Trial Shows
Novo Nordisk’s SOUL trial has shown that oral semaglutide reduces the risk of major adverse cardiovascular events (MACE) by ...
Wegovy Maker Novo Nordisk's Oral Diabetes Pill Cuts Heart Attacks, Stroke Events By 14%
Novo Nordisk's SOUL trial reveals a 14% reduction in major cardiovascular events with oral semaglutide in patients with type ...
The ‘C’ and ‘D’ of diabetes
Early control of HbA1c levels and weight in people with diabetes significantly reduces cardiac disease risk. Delays in ...